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httpcense.Abstract Background: COPD is characterized by air ﬂow limitation that is not fully reversed and
associated with an inﬂux of neutrophils, macrophages and CD8 T lymphocytes in the airways. The
disease is characterized by airﬂow limitation and is associated with an abnormal inﬂammatory
response of the lungs in response to noxious particles or gases and associated with systemic man-
ifestation.
Methods: Sixty consecutive patients with COPD and 40 normal healthy individuals were
included. All cases and controls were subjected to detection of 2 polymorphic loci (S1 AND Q1)
of ADAM33 by PCR-RFLP technique.
Results: The percentage of S1 and Q1 AA genotype and A allele were signiﬁcantly increased in
control than in COPD patients while there was signiﬁcant increase in S1 and Q1 GG genotype and
G allele in COPD patients than in control (p< 0.001). No signiﬁcant difference was found between
smoker and non-smoker among the two studied groups in genotype and alleles distribution of
ADAM33 SNPs S1 and Q1 p> 0.05, whereas there was signiﬁcant increase in ADAM33 S1 G
allele and Q1 G allele in smoker and non-smoker in COPD patients as compared to their
corresponding fellows in control group (p< 0.05). As regard to Pulmonary function test there
was signiﬁcant decrease in % of FEV1 in COPD patients as compared to control group for both
smokers and non-smokers (p< 0.001). Within both control and COPD groups smokers had
signiﬁcant decrease in FEV1 % as compared to non-smokers (p< 0.001). There was a signiﬁcantpartment of Chest diseases,
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276 A.H. Abd El-Zaher et al.decrease in FEV1 % among all genotypes in smoker as compared to non-smoker COPD patients
(p< 0.001), the most prominent decrease was found in smoker GG genotype for both ADAM33
S1 and Q1 in COPD patients.
Conclusion: In conclusion, we found that polymorphisms in the SNPs (Q1 and S1) of ADAM33
gene are associated with COPD in the general population. In addition, smoker patients with GG
genotype in (S1 and Q1) ADAM33 will have more pronounced decline in the pulmonary function
test (FEV1).
ª 2012 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.Introduction
Chronic obstructive pulmonary disease (COPD) is highly pre-
valent and the only disease with increasing mortality rates
worldwide [1]. The disease is characterized by air ﬂow limita-
tion that is not fully reversed and associated with an inﬂux
of neutrophils, macrophages and CD8 T lymphocytes in the
airways [2]. The disease is characterized by airﬂow limitation
and is associated with an abnormal inﬂammatory response
of the lungs in response to noxious particles or gases and asso-
ciated with systemic manifestation [3]. The severity of AHR is
positively associated with inﬂammation in lung tissue [4].
Tobacco smoking is the most important risk factor for
developing COPD. The deleterious effect of smoking is mainly
mediated through an accelerated decline in forced expiratory
volume in 1 s (FEV1) in adulthood, which over the years re-
sults in a substantial reduction in lung function leading to
symptomatic disease. Many longitudinal studies have provided
data on the increased relative risk of developing COPD in
smokers compared with non-smokers [5].
Genetic factors appear to predispose some individuals with
tobacco exposure to the development of smoking related respi-
ratory disease. Additionally, COPD tends to occur more fre-
quently in smokers with a family history of obstructive
airways disorders such as asthma and COPD [6,7].
ADAM33, is a member of the ADAM (a disintegrin and
metalloprotease) family. ADAM proteins are involved in cell
adhesion, cell fusion, cell signaling, and proteolysis [8]. The lat-
ter can be illustrated by the capacity to shed cytokines, growth
factors, or their receptors from the cell surface and the remod-
eling of extracellular matrix components. Garlisi demonstrated
that ADAM33 is an active proteinase that is able to cleave a2-
macroglobulin [9] and synthetic peptides [10].
It has been speculated that the ADAM33 gene is located on
chromosome 20p13 and 37 SNPs have initially been identiﬁed
[11], expressed in airway smooth muscle cells and ﬁbroblasts of
the lung, codes for a protein important for cell fusion, cell
adhesion, cell signaling and proteolysis. Furthermore,
ADAM33 was suggested to play a role in airway remodeling
[12].
SNPs within the ADAM33 locus are associated with accel-
erated decline of lung function in the general population and
in asthma patients [13,14]. The ADAM33 gene is expressed in
airway smooth muscle cells and ﬁbroblasts in the lung [15]. In
a longitudinal study from a general population, van Diemen
and coworkers showed associations between SNPs in
ADAM33 and annual decline in FEV1 in cigarette smokers
who were compared to the larger population [14]. These stud-
ies did not comprehensively investigate the genetic variationsobserved in the ADAM33 gene and were not performed in a
population of chronic cigarette smoker, the appropriate tar-
get population for studies of genetic susceptibility in COPD
[1].
The aim of the present study is to assess the role of the
SNPs of ADAM33 gene in smoker and non smoker COPD pa-
tients on the disease course.
Subjects and methods
We conducted a case-control study for COPD. The case
groups comprised 60 patients with stable COPD (36 men
and 24 women) with a mean age of 65.7 ± 8.03 years who
had not been previously treated with theophylline, b2-adrener-
gic receptor agonists, or glucocorticosteroids were recruited
from chest department, Tanta University Hospitals for this
study. The diagnosis of COPD was established using the fol-
lowing criteria: (1) history of cigarette smoking (a minimum
of 10 pack years) in patients who were current smokers at
the time of evaluation; (2) no exposure (occupational or other-
wise) to other substances known to cause lung disorders; (3)
absence of atopy; (4) no history of systemic or other pulmon-
ary disease or congenital and/or acquired systemic immunode-
ﬁciency; (5) forced expiratory volume in the ﬁrst second
(FEV1)/forced vital capacity (FVC) <70% and FEV1 after
inhalation of 200 mg salbutamol <80%. The control group
consisted of 40 unrelated healthy subjects 24 men and 16 wo-
men), Ventilatory function tests (FVC, FEV1 and FEV1%)
of all subjects were recorded using (spirolab II 125–00155,
ROMA, ITALY). with a mean age of 55.75 ± 5.86 years with
healthy pulmonary function and no known medical illnesses or
family disorders. They were matched for age, gender, and
smoking history with the case group.
Sampling
Blood samples (3 mL) were obtained from patients and con-
trols, collected to an EDTA tube for performing DNA extrac-
tion. All cases and controls were subjected to detection of 2
polymorphic loci (S1 AND Q1) of ADAM33 by PCR-RFLP
technique [16].Extraction of genomic DNA
Blood was collected in EDTA-tubes and stored at room tem-
perature until the genomic DNA was extracted using QIA
amp DNAMini Kit from QIAGEN according to the manufac-
turer‘ s instructions [16].
Figure 2 Agarose gel electrophoresis for RFLP-PCR product of
ADAM33 SNPs (Q1) stained with ethiduim bromide. M; repre-
sents DNA marker. Lanes 2, 4 & 5 represent homozygote AA
genotype. Lane 6 represent heterozygote AG genotype. Lanes 1, 3
& 7 represent homozygote GG genotype.
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Genotyping was performed by polymerase chain reaction-
restriction fragment length polymorphism (PCRRFLP) analy-
sis. The polymorphic region was ampliﬁed by PCR using a step
one real time PCR system (Applied Biosystems) in a 25 ll reac-
tion solution containing 0.3 lg genomic DNA, 10 · PCR buf-
fer, 0.3 mM MgCl2, 0.2 mM dNTPs, 2 U TaqDNA
polymerase (Takara, Japan), and 0.1 lmol of each primer







The PCR conditions for the detection of S1 were as fol-
lows: initial denaturation at 94 C for 5 min followed by 35 cy-
cles of 30 s at 94 C; 30 s at 50 C; 30 s at72 C and a ﬁnal
extension at 72 C for 5 min, while the PCR conditions for
the detection of Q1 were as follows: initial denaturation at
94 C for 5 min followed by 35 cycles of 30 s at 94 C; 30 s
at 60 C; 30 s at72 C and a ﬁnal extension at 72 C for 5 min.
PCR products were digested overnight with restriction en-
zymes Hinﬂ for S1 (NEB, UK) according to the manufac-
turer’s protocol and analyzed by agarose gel electrophoresis.
In the samples with a AA genotype the digestion resulted
304-bp band. In the samples carrying the mutation in hetero-
zygous form (AG), 132-, 172- and 304-bp digestion products
were detected. In the samples with a GG genotype, 132- and
172-bp products were formed (see Figs. 1 and 2).
We use BtsCl restriction enzymes for Q1 (NEB, UK)
according to the manufacturer’s protocol and analyzed by aga-
rose gel electrophoresis. In the samples with a AA genotype the
digestion resulted in 20- (non-visible), and 138-bp (visible)
bands. In the samples carrying the mutation in heterozygous
form (AG), 20- (non-visible), 138 and 158-bp (visible) diges-
tion products were detected. In the samples with a GG geno-
type, 158-bp (visible) products were formed.Figure 1 Agarose gel electrophoresis for RFLP-PCR product of
ADAM33 SNPs (S1) stained with ethiduim bromide. M; repre-
sents DNA marker. Lanes 1, 3 & 5 represent homozygote AA
genotype. Lanes 6 & 7 represent heterozygote AG genotype. Lanes
2 & 4 represent homozygote GG genotype.Statistical analysis
The statistical software package SPSS 15.0 was used for statisti-
cal calculations. Data are presented as mean ± SD for continu-
ous variables and as proportions for categorical variables.
Comparisons ofmeans between 2 groupswere analyzed by using
the Student unpaired t-test while comparisons of means among
3 groupswere performed using one-wayANOVA test. The allele
and genotype frequencies among cases and controls were com-
pared byChi-square test andodds ratiowith 95%CI.Two-tailed
P-value of 60.05 was considered signiﬁcant.
Results
This study was performed on 60 subjects with chronic obstruc-
tive pulmonary disease (COPD) with mean age was
46.7 ± 8.03 years and 40 normal healthy subjects as control
group with mean age was 45.75 ± 5.86 years. The both groups
(control & COPD) were matched as regards to age and sex
with male predominance as M/F ratio was (24/16, 36/24)
respectively all other Clinical characteristics of studied groups
were shown in (Table 1).
Table 2 illustrates genotype and alleles of ADAM33 SNPs
(S1 and Q1) in chronic obstructive pulmonary disease (COPD)
and control. The percentage of S1 and Q1 AA genotype and A
allele were signiﬁcantly increased in control than in COPD pa-
tients while there was signiﬁcant increase in S1 and Q1 GG
genotype and G allele in COPD patients than in control
(p< 0.001). The frequency of ADAM33 S1 G allele and Q1
G allele were signiﬁcantly higher in COPD patients than in
control (p< 0.001, OR = 0.171, 95% CI = 0.091  0.321;Table 1 Clinical characteristics of studied groups.
Control COPD
Number of patients 40 60
Age (years) 55.75 ± 5.86 56.7 ± 8.03
Male: female 24/16 36/24
Pack years of smoking 31.44 34.51
FEV1 (% predicted) 86.65 ± 5.96 56.02 ± 7.71
Table 2 Prevalence of ADAM33 SNPs (S1 and Q1) in all studied groups.
ADAM33 SNPs Control COPD P-value Odd ratio
N % N % Value L U
S1 AA 25 62.50 14 23.33 0.000* 5.476 2.280 13.152
AG 9 22.50 11 18.33 0.396 1.293 0.481 3.477
GG 6 15.00 35 58.33 0.000* 0.126 0.046 0.345
A allele 59 73.75 39 32.50 0.000* 5.835 3.115 10.931
G allele 21 26.25 81 67.50 0.000* 0.171 0.091 0.321
Q1 AA 26 65.00 18 30.00 0.001* 4.333 1.847 10.165
AG 11 27.50 13 21.67 0.331 1.371 0.543 3.465
GG 3 7.50 29 48.33 0.000* 0.087 0.024 0.312
A allele 63 78.75 49 40.83 0.000* 5.370 2.810 10.262
G allele 17 21.25 71 59.17 0.000* 0.186 0.097 0.356
* Signiﬁcance p6 0.001.
Table 3 Prevalence of ADAM33 SNPs (S1 and Q1) in all studied groups.
ADAM33 SNPs Control COPD P1 P2 P3 P4
Smoker Non smoker Smoker Non smoker
N % N % N % N %
S1 AA 11 44.00 7 46.67 9 22.50 4 20.00 0.564 0.552 0.061 0.095
AG 8 32.00 5 33.33 7 17.50 3 15.00 0.599 0.559 0.148 0.192
GG 6 24.00 3 20.00 24 60.00 13 65.00 0.546 0.466 0.005 0.010
A allele 30 60.00 19 63.33 25 31.25 11 27.50 0.478 0.420 0.001 0.003
G allele 20 40.00 11 36.67 55 68.75 29 72.50 0.478 0.420 0.001 0.003
Q1 AA 13 52.00 8 53.33 7 17.50 3 15.00 0.597 0.559 0.004 0.020
AG 5 20.00 4 26.67 12 30.00 5 25.00 0.454 0.466 0.276 0.606
GG 7 28.00 3 20.00 21 52.50 12 60.00 0.432 0.393 0.045 0.020
A allele 31 62.00 20 66.67 26 32.50 11 27.50 0.431 0.367 0.001 0.001
G allele 19 38.00 10 33.33 54 67.50 29 72.50 0.431 0.367 0.001 0.001
P1 – Smoker and non smoker in control group.
P2 – Smoker and non smoker in COPD group.
P3 – Control and COPD in smoker group.
P4 – Control and COPD in non smoker group.
Table 4 Pulmonary function test FEV1 (% predicted) in all studied groups.
FEV1 (% predicted)
Control COPD T-test
N Mean ± SD N Mean ± SD t P-value
Smoker 25 78.156 ± 4.33 40 50.64 ± 6.884 17.869 <0.001*
Non smoker 15 100.81 ± 7.68 20 66.785 ± 8.81 11.931 <0.001*
T-test t 11.971 7.789
P-value <0.001* <0.001*
* Signiﬁcance p6 0.001.
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respectively).
Table 3 shows no signiﬁcant difference was found between
smoker and non-smoker among the two studied groups in
genotype and alleles distribution of ADAM33 SNPs S1 and
Q1 p> 0.05, whereas there was signiﬁcant increase in
ADAM33 S1 G allele and Q1 G allele in smoker and non-smo-
ker in COPD patients as compared to their corresponding fel-
lows in control group (p< 0.05).As regard to Pulmonary function test there was signiﬁcant
decrease in% of FEV1 in COPD patients as compared to con-
trol group for both smokers and non-smokers (p< 0.001).
Within both control and COPD groups smokers had signiﬁ-
cant decrease in FEV1% as compared to non-smokers
(p< 0.001) Table 4.
There was a signiﬁcant decrease in FEV1% among all geno-
types in smoker as compared to non-smoker COPD patients
(p< 0.001), the most prominent decrease was found in smoker
Table 5 Pulmonary function test FEV1 (% predicted) in ADAM33 SNPs (S1 and Q1) of COPD group.
ADAM33 SNPs FEV1 (% predicted)
Smoker Non smoker T-test
N Mean ± SD N Mean ± SD t P-value
S1 AA 9 58.2 ± 1.563 4 73.8 ± 1.02 18.085 <0.001*
AG 7 52.44 ± 1.11 3 71.62 ± 0.65 27.391 <0.001*
GG 24 46.8 ± 1.91 13 66.8 ± 1.088 34.688 <0.001*
ANOVA F 16.542 13.55
P-value <0.001* <0.001*
Q1 AA 7 58.9 ± 1.055 3 75.27 ± 0.779 23.884 <0.001*
AG 12 53.33 ± 0.871 5 71.8 ± 1.16 26.272 <0.001*
GG 21 47.912 ± 1.721 12 68.3 ± 1.41 34.832 <0.001*
ANOVA F 14.664 15.56
P-value <0.001* <0.001*
* Signiﬁcance p6 0.001.
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(see Table 5).
Discussion
COPD is the ﬁfth leading cause of mortality in 2001 worldwide
according to the World Health Organization. Because the
prevalence and mortality due to COPD are expected to in-
crease, this disease will become an even larger social and eco-
nomic burden [17].
In this study we genotyped 2 SNPs in ADAM33 gene (S1
and Q1) in COPD patients. It was found that there was signif-
icant increase in S1 and Q1 GG genotype and G allele in
COPD patients as compared to control. These results were
in accordance with another study of van Diemen et al. who re-
ported that In a Dutch population, the SNPs S1, S2, and Q1
were associated with FEV1 decline, and the SNPs S1, S2,
F+1, and T2 were associated with the presence of COPD [17].
A study by Gosman et al. found that prevalence of the
ADAM33 SNPs in their COPD population was comparable
to those recently reported by van Diemen et al. [17] and minor
alleles for SNPs F+1, S_1 and S_2 were more prevalent in pa-
tients with COPD than in healthy participants. Regarding SNP
Q1 they showed a signiﬁcantly higher prevalence of the min-
or allele in patients with COPD compared with healthy con-
trols [18].
The SNP Q1 is located in the intron immediately before
exon 16, which contains an epidermal growth factor (EGF) do-
main [19]. EGF signaling is important in lung morphogenesis.
EGFR signaling regulates matrix metalloproteases, which
mediate epithelial–mesenchymal interactions during lung mor-
phogenesis [20]. ADAM33 is closely related to matrix metallo-
proteases, but may bind EGF directly. A disturbance in the
EGF domain will likely affect regulation of ADAM33.
Through alterative splicing, exon 16 can be spliced out, giving
rise to the b-variant of ADAM33. This variant was found in
30% of ADAM33 mRNA transcripts in pulmonary ﬁbroblasts
[21]. Because the EGF domain is incomplete, it has been sug-
gested that the b-variant prevents maturation of ADAM33
and may exert a dominant-negative effect on its protease activ-
ity [22].The intronic Q1 SNP may therefore inﬂuence thesplicing of the b-variant [23] and disturb the maturation of
ADAM33. 2.
The most appropriate control group for studies on COPD
should consist of chronic cigarette smokers who are at risk
for COPD and yet have normal lung function. To this end,
the controls in this report have comparable exposure to tobac-
co smoke as the affected cases [1].
Although smoking is considered a risk factor for predispos-
ing COPD, this study did not found signiﬁcant association be-
tween smoking and genotypic distribution of ADAM33 SNPs
S1 and Q1 in both groups, but there was signiﬁcant decrease in
% of FEV1 in COPD patients as compared to control group
for both smokers and non-smokers. Within both control and
COPD groups smokers had signiﬁcant decrease in FEV1 %
as compared to non-smoker.
These results were in accordance with a study of Sadeghn-
jad et al. who found a relationship between ADAM33 varia-
tion and COPD in a Dutch general population including
smokers and non-smokers. This study showed that individuals
homozygous for the minor alleles of SNPs S2 and Q1 and
heterozygous for SNP S1 had an excess annual decline in
FEV1 compared to their respective wild type in subjects with
COPD compared to the entire general population that in-
cluded non-smokers [1].
O’Shaughnessy et al. showed an increased number of neu-
trophils and CD8 lymphocytes in bronchial biopsies of smok-
ers with air ﬂow limitation, and this increase was inversely
associated with the level of lung function. We, therefore,
hypothesized that individuals with a genetic predisposition
for a higher number of CD8 cells were more susceptible to a
further increase in CD8 cells, which might ﬁnally result in air
ﬂow limitation. Interestingly, we found an association of
SNP ST+5 with both the presence of COPD (see online data
repository) and the number of CD8 cells in our patients with
COPD [24].
There is an association between ADAM33 and the severity
of airway hyper-responsiveness (AHR) in COPD. AHR is
important to COPD given its association with accelerated
FEV1 decline and increased risk of COPD mortality. The ex-
act pathophysiology underlying AHR is unclear, but it is
thought to result from an inﬂammatory process in the airways
280 A.H. Abd El-Zaher et al.in addition to geometric changes owing to airway remodeling.
It is possible that ADAM33 has a role in both these processes
thereby contributing to the severity of AHR [25].
SNPs S_1 was associated with both excessive FEV1 decline
in the general population and development of COPD. These
SNPs are located in exon S, which encodes the transmembrane
region. The S_1 SNP causes an amino acid change (valine to
isoleucine), but it is unknown whether this also modiﬁes the
structure of the protein. If so, the ADAM33 protein may not
be anchored correctly in the membrane and therefore may
not be able to exert its function [17].
Conclusion
We found that polymorphisms in the SNPs (Q1 and S1) of
ADAM33 gene are thought to be associated with COPD. In
addition, smokers among COPD patients who have GG geno-
type in (S1 and Q1) ADAM33 gene will have more pro-
nounced decline in the pulmonary function test (FEV1)
during the course of the disease.
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